Myeloma

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination and what its approval by the FDA would mean for patients.

Two people have transformed my journey from pain into possibility. In their presence, I find the strength to continue. Together, they've taught me that even in collapse and ill health, life can bloom again.

In patients with relapsed/refractory multiple myeloma, Tecvayli monotherapy is associated with a 71% reduction in the risk of disease progression or death.

A stage 3 multiple myeloma diagnosis is significant, but new therapies are changing the outlook. Learn about your potential next steps.

Reach out to professionals, go to safe online sources, contact your local cancer support center. I hope these tools help you as they have helped me.

I reflect on a year of healing, family, and meaningful rituals while setting intentions for 2026 with vision, consistency and awakening.

Diagnosed with myeloma in 2017, Oya Gilbert highlights self-advocacy, emotional well-being and culturally relevant outreach for underserved patients.

Living with an incurable cancer that resists durable remission means holding hope and grief at the same time — existing between promising data and lived experience.

Treatment with Lynozyfic showed early responses and a manageable safety profile in patients with newly diagnosed multiple myeloma.

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

KRd improved progression-free survival, deepened responses, and led to higher MRD negativity versus VRd in patients with newly diagnosed multiple myeloma.

In patients with R/R multiple myeloma, real-world Elrexfio was associated with shorter time until progression but higher rates of response than Tecvayli.

I found purpose again after my myeloma diagnosis when I returned to teaching and shared my work, moments that reminded me I could still grow and reconnect.

I explain how the words caregiver and incurable shaped my wife’s cancer journey and why I believe more hopeful language better reflects our experience.

Todd Kennedy, a multiple myeloma survivor, explains how switching from an hours-long IV infusion to a 3-minute Sub-Q injection changed his life.

Stage 2 multiple myeloma can feel overwhelming. Learn what it means, treatment options, and key questions to discuss with your oncologist.

Kimberly Alexander urges care partners to seek support, prioritize self-care and push for better awareness so families in the Black community aren’t overlooked.

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma.

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

CURE contributor Ronald D. Chin received a diagnosis of multiple myeloma in 2017 and has been in remission since 2023.

The FDA has approved Blenrep with BVd as a third-line treatment for relapsed or refractory multiple myeloma.

CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.

The FDA approved Blenrep with Velcade and dexamethasone for relapsed or refractory multiple myeloma.

The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma.